CVS readies a set of outcomes-based contracts for its clients

While announcing its annual update of drugs (now around 36) to be excluded from its “Standard Control Formulary” in 2018, the industry-leading pharmacy benefit manager (PBM) is also hinting at another cost-control measure: outcomes-based contracting. Such programs have been occasionally entered […]

Read More

New science energizes the cancer market

Oncology drugs have had a prominent position in the biopharma industry, as well as healthcare generally, because the stakes are so high: cancer is often fatal; in its many forms, it is a common health condition; and, in recent years, […]

Read More